Verrica Pharmaceuticals
VRCA
74 hedge funds and large institutions have $13M invested in Verrica Pharmaceuticals in 2025 Q1 according to their latest regulatory filings, with 9 funds opening new positions, 30 increasing their positions, 10 reducing their positions, and 16 closing their positions.
200% more repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 10
0.1% less ownership
Funds ownership: 3.32% → 3.21% (-0.1%)
9% less funds holding
Funds holding: 81 → 74 (-7)
38% less capital invested
Capital invested by funds: $21M → $13M (-$7.95M)
44% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 16
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CP
Caligan Partners
New York
|
+$1.01M |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$398K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$350K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$311K |
| 5 |
Millennium Management
New York
|
+$256K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
-$2.27M |
| 2 |
HCM
Heights Capital Management
San Francisco,
California
|
-$246K |
| 3 |
AC
Armistice Capital
New York
|
-$229K |
| 4 |
Morgan Stanley
New York
|
-$189K |
| 5 |
Renaissance Technologies
New York
|
-$163K |
VRCA Hedge Fund Activity: Q1 2025 in Review
74 of the 7,458 institutional investors tracked by Wall St. Rank reported a position in Verrica Pharmaceuticals (VRCA) for Q1 2025, worth a combined $13M — down 38% from $21M a quarter earlier.
Sellers outnumbered buyers: 16 funds closed out of VRCA and 9 opened new positions — a net loss of 7 holders — while 10 trimmed existing stakes and 30 added.
The largest buyer was Caligan Partners, adding an estimated $1.01M. The largest seller was Perceptive Advisors, exiting entirely with an estimated $2.27M sold.
- 74 institutional investors held Verrica Pharmaceuticals (VRCA) as of Q1 2025, down from 81 in Q4 2024.
- Funds reported $13M of Verrica Pharmaceuticals stock for Q1 2025, down 38% quarter-over-quarter.
- 9 funds opened new Verrica Pharmaceuticals positions in Q1 2025 and 16 closed out, a net change of -7 holders.
- The largest Verrica Pharmaceuticals buyer in Q1 2025 was Caligan Partners, an estimated $1.01M added.
- The largest Verrica Pharmaceuticals seller in Q1 2025 was Perceptive Advisors, an estimated $2.27M sold.
Based on aggregated 13F filings for Q1 2025.